A potent adjuvant effect of a CD1d-binding NKT cell ligand in human immune system mice

References

• World Health Organization (WHO): World Malaria Report 2014. http://www.who.int/malaria/publications/world_malaria_report_2014/en/
   Google Scholar
• Crompton PD, Pierce SK, Miller LH. Advances and challenges in malaria vaccine development. J Clin Invest. 2010;120:4168–4178.
   PubMed Web of Science ®Google Scholar
• Nussenzweig RS, Vanderberg J, Most H, et al. Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature. 1967;216:160–162.
   PubMed Web of Science ®Google Scholar
• Gwadz RW, Cochrane AH, Nussenzweig V, et al. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of plasmodium knowlesi and characterization of surface antigens of these parasites. Bull World Health Organ. 1979;57(Suppl 1):165–173.
   PubMedGoogle Scholar
• Clyde DF, McCarthy VC, Miller RM, et al. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am J Med Sci. 1973;266:398–403.
   PubMed Web of Science ®Google Scholar
• Herrington D, Davis J, Nardin E, et al. Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals. Am J Trop Med Hyg. 1991;45:539–547.
   PubMed Web of Science ®Google Scholar
• Hoffman SL, Goh LM, Luke TC, et al. Protection of humans against malaria by immunization with radiation-attenuated plasmodium falciparum sporozoites. J Infect Dis. 2002;185:1155–1164.
   PubMed Web of Science ®Google Scholar
• Epstein JE, Tewari K, Lyke KE, et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science. 2011;334:475–480.
   PubMed Web of Science ®Google Scholar
• Seder RA, Chang L, Enama ME, et al. Protection against malaria by intravenous immunization with a non-replicating sporozoite vaccine. Science. 2013;341:1359–1365.
   PubMed Web of Science ®Google Scholar
• Roestenberg M, McCall M, Hopman J, et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med. 2009;361:468–477.
   PubMed Web of Science ®Google Scholar
• Bartkowiak T, Singh S, Yang G, et al. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc Natl Acad Sci U S A. 2015;112:E5290- E9.
   PubMed Web of Science ®Google Scholar
• Venkataswamy MM, Baena A, Goldberg MF, et al. Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of mycobacterium bovis bacillus Calmette-Guerin. J Immunol. 2009;183:1644–1656.
   PubMed Web of Science ®Google Scholar
• Huang Y, Chen A, Li X, et al. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide. Vaccine. 2008;26:1807–1816.
   PubMed Web of Science ®Google Scholar
• Ko SY, Ko HJ, Chang WS, et al. alpha-galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol. 2005;175:3309–3317.
   PubMed Web of Science ®Google Scholar
• Hermans IF, Silk JD, Gileadi U, et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol. 2003;171:5140–5147.
   PubMed Web of Science ®Google Scholar
• Fujii S, Shimizu K, Smith C, et al. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med. 2003;198:267–269.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC, et al. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med. 2002;195:617–624.
   PubMed Web of Science ®Google Scholar
• Li X, Fujio M, Imamura M, et al. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci USA. 2010;10:13010–13015.
   Web of Science ®Google Scholar
• Li X, Kawamura A, Andrews CD, et al. Colocalization of a CD1d-binding glycolipid with a radiation-attenuated sporozoite vaccine in lymph node-resident dendritic cells for a robust adjuvant effect. J Immunol. 2015;195:2710–2721.
   PubMed Web of Science ®Google Scholar
• Padte NN, Boente-Carrera M, Andrews CD, et al. A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates. PLoS One. 2013;8:e78407.
   PubMed Web of Science ®Google Scholar
• Padte NN, Li X, Tsuji M, et al. Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Clin Immunol. 2011;140:142–151.
   PubMed Web of Science ®Google Scholar
• Huang J, Li X, Coelho-dos-Reis JG, et al. An AAV vector-mediated gene delivery approach facilitates reconstitution of functional human CD8+ T cells in mice. PLoS One. 2014;9:e88205.
   PubMed Web of Science ®Google Scholar
• Barzaga-Gilbert E, Grass D, Lawrance SK, et al. Species specificity and augmentation of responses to class II major histocompatibility complex molecules in human CD4 transgenic mice. J Exp Med. 1992;175:1707–1715.
   PubMed Web of Science ®Google Scholar
• Li X, Huang J, Zhang M, et al. Human CD8+ T cells mediate protective immunity induced by a human malaria vaccine in human immune system mice. Vaccine. 2016;34:4501–4506.
   PubMed Web of Science ®Google Scholar
• Shiratsuchi T, Schneck J, Kawamura A, et al. Human CD1 dimeric proteins as indispensable tools for research on CD1-binding lipids and CD1-restricted T cells. J Immunol Methods. 2009;345:49–59.
   PubMed Web of Science ®Google Scholar
• Lepus CM, Gibson TF, Gerber SA, et al. Comparison of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell engraftment in NOD-scid/gammac-/-, Balb/c-Rag1-/-gammac-/-, and C.B-17-scid/bg immunodeficient mice. Hum Immunol. 2009;70:790–802.
   PubMed Web of Science ®Google Scholar
• Liu Y, Goff RD, Zhou D, et al. A modified alpha-galactosyl ceramide for staining and stimulating natural killer T cells. J Immunol Methods. 2006;312:34–39.
   PubMed Web of Science ®Google Scholar
• Blum-Tirouvanziam U, Servis C, Habluetzel A, et al. Localization of HLA-A2.1-restricted T cell epitopes in the circumsporozoite protein of plasmodium falciparum. J Immunol. 1995;154:3922–3931.
   PubMed Web of Science ®Google Scholar
• Zhang M, Kaneko I, Tsao T, et al. A highly infectious plasmodium yoelii parasite, bearing plasmodium falciparum circumsporozoite protein. Malar J. 2016;15:201.
   PubMed Web of Science ®Google Scholar
• Richie TL, Billingsley PF, Sim BK, et al. Progress with plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine. 2015;33:7452–7461.
   PubMed Web of Science ®Google Scholar
• Hollingdale MR, Sedegah M. Development of whole sporozoite malaria vaccines. Expert Rev Vaccines. 2016;18:1–10.
   Google Scholar